# Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece

Source: https://onco.cc/trials/nct03755791/  
OnCo record `nct03755791` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabozantinib, Sorafenib, Atezolizumab in hepatocellular carcinoma, run by Exelixis, active and no longer recruiting.

## Summary

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy is a phase 3 interventional study registered as NCT03755791 by Exelixis, with 837 participants enrolled, started 2018-06-10 and due to reach its primary completion in 2021-11-30. Interventions recorded: Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab. Conditions listed: Hepatocellular Carcinoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: COSMIC-312
- Tags: ctgov-ingest
- Registry id: NCT03755791
- Phase: 3
- Setting: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
- Sponsor: Exelixis
- Enrolled: 837
- Outcomes: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population: Experimental Arm: Cabozantinib + Atezolizumab 6.8 months vs Control Arm: Sorafenib 4.21 months, HR 0.63; Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population: Experimental Arm: Cabozantinib + Atezolizumab 16.46 months vs Control Arm: Sorafenib 15.51 months, HR 0.99

## Sources

- ClinicalTrials.gov NCT03755791: https://clinicaltrials.gov/study/NCT03755791

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Sorafenib](https://onco.cc/drugs/sorafenib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)
- ideas: [Immunotherapy downstaging to transplant with a safe washout](https://onco.cc/ideas/idea-hcc-io-before-transplant/)

---
JSON: https://onco.cc/api/v1/entities/nct03755791.json